5 / 7
Page 77
Notes:
conferenceseries
.com
Volume 3
Optometry: Open Access
ISSN: 2476-2075
Optometry 2018
October 08-09, 2018
October 08-09, 2018 | Edinburgh, Scotland
3
rd
International Conference and Expo on
Optometry & Vision Science
Treatments for dry eye disease: A comparison analysis
F. Buck Willis
Academy of Integrative Health & Medicine (AIHM), USA
Description:
The purpose of this meeting is to examine and discuss the evidence-based comparisons of the current treatments
for Dry Eye Disease (DED).
Introduction:
Dry Eye Disease (DED) effects up to 30% of the global population (2.25 Billion people) and this inflammatory
condition of ocular surfaces has symptoms of visual disturbances, eye discomfort, tear film instability, etc. In the United States
the average cost of treating this anomaly is over $6,500 with incidence rate of up to 20 million patients. This meeting will discuss
three primary treatments of Cyclosporine 5%, Lifitegrast, and studies showing significance and differences between these
treatments. A recent Systematic Review with meta-analysis was conducted on studies of Topical Cyclosporine 5% (Restasis®;
Allergan, Inc., Irvine, CA). The 12 studies (mean 25 weeks) included 629 subjects receiving treatment of Restasis. The outcome
measure shared between these studies was the Schirmer #1 test and the mean score reduction was 2.7mm. A retrospective case/
control study was conducted, measuring efficacy of Lifitegrast (Xiidra® Shire, Inc. Lexington, MA) versus other treatments
in over 2,000 eyes. The mechanism of action is different than Cyclosporine because Lifitegrast reduces ocular inflammation
as an integrin antagonist that blocks binding of ICAM-1 to LFA-1 on the T-cell surfaces. Testing in this investigation was
accomplished with Schirmer’s tests, Corneal staining, and tear film Break Up Time (tBUT) in different sub populations. Even
with different testing mechanisms, these Lifitegrast patients showed significant changes, particularly in short-term follow ups.
Optom open access 2018, Volume 3
DOI: 10.4172/2476-2075-C1-009